MiR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  Amodio, N ^a   Di Martino, M T ^a   Foresta, U ^a   Leone, E ^a   Lionetti, M ^b   Leotta, M ^a   Gulla A M ^a   Pitari, M R ^a   Conforti, F ^a   Rossi, M ^a   Agosti, V ^a   Fulciniti, M ^c,d   Misso, G ^e   Morabito, F ^f   Ferrarini, M ^g   Neri, A ^b   Caraglia, M ^e   Munshi, N C ^c,d   Anderson, K C ^c   Tagliaferri, P ^a   Tassone, P ^a,h   more..

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f Azienda Ospedaliera Annunziata   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h TEMPLE UNIVERSITY   (United States)

Author keywords

Bortezomib; MicroRNA; miR 29b; miRNAs; Multiple myeloma; Plasma cell leukemia; Sp1

Indexed keywords

BORTEZOMIB; DNA 26S; LENTIVIRUS VECTOR; MICRORNA 29B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; BORONIC ACIDS; DOWN-REGULATION; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; PYRAZINES; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

LENTIVIRUS;

EID: 84870543762     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.175     Document Type: Article

References (58)

1. Pattanayak D, Agarwal S, Sumathi S, Chakrabarti SK, Naik PS, Khurana SM. Small but mighty RNA-mediated interference in plants. Indian J Exp Biol 2005; 43: 7-24.
2. Hutvagner G, Small RNA. asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett 2005; 579: 5850-5857
3. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
4. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203-1217.
5. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563-568.
6. Fabbri M, Croce CM, Calin GA. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 2009; 50: 160-170.
7. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-1138.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
9. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
10. Czech MP. MicroRNAs as therapeutic targets. N Engl J Med 2006; 354: 1194-1195.
11. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
12. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
13. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923-5930.
14. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD et al. Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146-1183.
15. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
16. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12 757-767.
17. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-937.
18. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38: 250-259.
19. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
20. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol 2003; 40: 33-38.
21. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics 2004CA Cancer J Clin 2004; 54: 8-29.
22. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z et al. A highaffinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009; 15: 7144-7152.
23. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379.
24. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008; 22: 1410-1418.
25. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251-4258.
26. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR et al. Synthetic miR- 34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260-6270.
27. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 823-837.
28. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 838-846.
29. Le Beau MM, Espinosa R 3rd, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930-1935.
30. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590-11593.
31. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140.
32. Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ et al. Overexpression of microRNA- 29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun 2011; 414: 233-239.
33. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23-29.
34. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
35. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105: 5874-5878.
36. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331-5341.
37. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NFkappaB. J Cell Biochem 2010; 110: 1155-1164.
38. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369-381.
39. Zheng L, Lee WH. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001; 264: 2-18.
40. Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011; 17: 6500-6509.
41. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 2007; 26: 753-767.
42. Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest 1989; 83: 2003-2007.
43. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
44. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. Sp1/NFkappaB/HDAC/miR- 29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333-347.
45. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116: 406-417.
46. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345-6350.
47. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
48. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
49. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
50. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364-2373.
51. Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009; 48: 199-209.
52. Molineaux SM. Molecular pathways: targeting proteasomal protein degradation in cancer. Clin Cancer Res 2012; 18: 15-20.
53. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046-1052.
54. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009; 8: 648-653.
55. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK et al. Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012; [e-pub ahead of print].
56. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K et al. Integrative highresolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009; 48: 521-531.
57. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 2010; 177: 2622-2634.
58. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.